LPS and 2,7-dichlorofluorescein diacetate were purchased from SigmaAldrich (St
BPC-157 and TB-500 also reduce inflammation in animal studies, but as a secondary effect of their tissue-repair pathways, not as a primary mechanism
Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al
Optimising glycaemic control represents the most important disease-modifying intervention, with evidence demonstrating that improved HbA1c can slow neuropathy progression, though reversal of established nerve damage remains limited
The STEP 1 trial showed participants lost an average of 14.9% of their body weight over 68 weeks at the 2.4mg dose
Advances in precision medicine could allow clinicians to tailor therapies based on genetic and metabolic profiles